Palisade Bio Q3 EPS Decreased by Brookline Capital Markets

Key Points

• Brookline Capital Markets lowered Palisade Bio’s Q3 2026 EPS estimate to a loss of $0.06 per share from a prior estimate of $0.05, while projecting continued losses through 2029.
• Palisade Bio’s latest results matched expectations, with a quarterly loss of $0.05 per share and revenue of $0.50 million. Analysts maintain an overall “Buy” consensus rating with an average price target of $9.00.
• The stock opened at $2.15, up 0.5%, and has risen from a 52-week low of $0.53; institutional investors own 11.79% of the company, while recent insider activity included both director purchases and an insider sale tied to tax withholding.

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Stock analysts at Brookline Capital Markets decreased their Q3 2026 earnings estimates for shares of Palisade Bio in a research report issued to clients and investors on Friday, August 14th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings per share of ($0.06) for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Palisade Bio's current full-year earnings is ($0.22) per share. Brookline Capital Markets also issued estimates for Palisade Bio's Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.38) EPS.

Palisade Bio (NASDAQ:PALI - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05). The firm had revenue of $0.50 million during the quarter, compared to analysts' expectations of $0.50 million.

Other research analysts have also issued reports about the stock. Weiss Ratings lowered shares of Palisade Bio from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, July 14th. LADENBURG THALM/SH SH upgraded Palisade Bio to a "strong-buy" rating in a research note on Thursday, June 25th. HC Wainwright reissued a "buy" rating and issued a $2.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. Wall Street Zen upgraded Palisade Bio from a "sell" rating to a "hold" rating in a research note on Saturday, July 25th. Finally, Oppenheimer began coverage on Palisade Bio in a report on Thursday, July 23rd. They set an "outperform" rating and a $8.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Palisade Bio currently has an average rating of "Buy" and an average price target of $9.00.

Palisade Bio Stock Up 0.5%

PALI stock opened at $2.15 on Tuesday. The company has a market capitalization of $374.68 million, a PE ratio of -2.13 and a beta of 1.52. The stock's 50 day moving average is $1.96 and its two-hundred day moving average is $1.92. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.86.

Institutional Investors Weigh In On Palisade Bio

Large investors have recently bought and sold shares of the business. Cetera Investment Advisers bought a new position in Palisade Bio during the fourth quarter valued at about $25,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Palisade Bio during the 4th quarter worth about $26,000. Virtu Financial LLC bought a new position in shares of Palisade Bio in the 4th quarter valued at approximately $28,000. Legal & General Group Plc bought a new stake in Palisade Bio during the second quarter worth approximately $30,000. Finally, CTC Alternative Strategies Ltd. acquired a new position in Palisade Bio during the first quarter valued at approximately $31,000. 11.79% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Palisade Bio news, Director Robert Jr. Baltera bought 30,000 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were purchased at an average cost of $2.03 per share, for a total transaction of $60,900.00. Following the transaction, the director directly owned 416,904 shares in the company, valued at $846,315.12. The trade was a 7.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mitchell Lawrence Jones sold 51,880 shares of the firm's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total transaction of $106,354.00. Following the completion of the transaction, the insider directly owned 94,009 shares of the company's stock, valued at $192,718.45. This represents a 35.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have acquired 125,000 shares of company stock valued at $250,100 over the last quarter. Insiders own 0.07% of the company's stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source